Arsanis (ASNS) Issues Earnings Results

Arsanis (NASDAQ:ASNS) released its earnings results on Friday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02), MarketWatch Earnings reports.

Shares of NASDAQ:ASNS traded down $0.06 during mid-day trading on Friday, reaching $1.37. The stock had a trading volume of 857,225 shares, compared to its average volume of 198,372. The company has a market capitalization of $19.75 million and a price-to-earnings ratio of -0.08. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.54 and a quick ratio of 5.54. Arsanis has a twelve month low of $1.25 and a twelve month high of $28.69.

ASNS has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Arsanis from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. ValuEngine upgraded shares of Arsanis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Piper Jaffray Companies cut their price target on shares of Arsanis to $2.50 and set a “neutral” rating on the stock in a research report on Monday, August 13th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $14.88.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/11/10/arsanis-asns-issues-earnings-results.html.

About Arsanis

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Featured Story: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply